Bevacizumab for Central Retinal Vein Occlusion Study
- Sponsor
- Anders Kvanta
- Study ID
- NCT00906685
- Phase
- PHASE3
- Status
- Completed
Conditions
- Central Retinal Vein Occlusion
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - N/A
- Healthy Volunteers
- Not accepted
Interventions
- bevacizumab — DRUGIntravitreal injection of 1.25 mg bevacizumab
- Sham bevacizumab injection — DRUGSham intravitreal injection
Study Details
Central retinal vein occlusion is a leading cause of severe visual impairment. Until now, no treatment has been available to improve visual acuity. The present study intends to investigate if intravitreal bevacizumab can improve visual acuity as compared to sham-treated control patients.
Key Dates
- First listed
- May 21, 2009
- Start date
- May 31, 2009
- Status verified
- Nov 2011
- Primary completion
- Mar 31, 2011
- Completion
- Sep 30, 2011
Study Design
- Enrollment
- 60 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: Intravitreal bevacizumab
- Sham Comparator: Sham injection
Primary Outcome Measure
The proportion of patients gaining 15 ETDRS letters or more [ Time Frame: 6 months ]